A prediction model to calculate probability of Alzheimer’s disease using cerebrospinal fluid biomarkers

We aimed to develop a prediction model based on cerebrospinal fluid (CSF) biomarkers, that would yield a single estimate representing the probability that dementia in a memory clinic patient is due to Alzheimer's disease (AD).

[1]  S. le Cessie,et al.  Predictive value of statistical models. , 1990, Statistics in medicine.

[2]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[3]  P. Visser,et al.  Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.

[4]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[5]  K. Langa,et al.  Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study , 2007, Neuroepidemiology.

[6]  M. Verbeek,et al.  Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases , 2003, Annals of clinical biochemistry.

[7]  M. O. Olde Rikkert,et al.  Current state and future directions of neurochemical biomarkers for Alzheimer's disease. , 2007, Clinical chemistry and laboratory medicine.

[8]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[9]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[10]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[11]  P. Scheltens,et al.  Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. , 2004, Neurology.

[12]  E. Perry,et al.  Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies , 2010, International journal of Alzheimer's disease.

[13]  F. Verhey,et al.  The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. , 2010, Current Alzheimer research.

[14]  M. Olde Rikkert,et al.  Experiences with cerebrospinal fluid analysis in Dutch memory clinics , 2011, European journal of neurology.

[15]  Ewout W Steyerberg,et al.  Validation and updating of predictive logistic regression models: a study on sample size and shrinkage , 2004, Statistics in medicine.

[16]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[17]  D. Mark,et al.  Clinical prediction models: are we building better mousetraps? , 2003, Journal of the American College of Cardiology.

[18]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[19]  H M Huizenga,et al.  Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease , 2009, Psychological Medicine.

[20]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[21]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[22]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[23]  P. Scheltens,et al.  Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease , 2004, Neurology.

[24]  Kenneth Rockwood,et al.  How golden is the gold standard of neuropathology in dementia? , 2011, Alzheimer's & Dementia.

[25]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[26]  Marion Smits,et al.  Predicting Intracranial Traumatic Findings on Computed Tomography in Patients with Minor Head Injury: The CHIP Prediction Rule , 2007, Annals of Internal Medicine.

[27]  W. M. van der Flier,et al.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.

[28]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[29]  Y Vergouwe,et al.  Updating methods improved the performance of a clinical prediction model in new patients. , 2008, Journal of clinical epidemiology.

[30]  M. Verbeek,et al.  Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. , 2006, The journals of gerontology. Series A, Biological sciences and medical sciences.

[31]  J. Viña,et al.  Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.

[32]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[33]  Martha Sajatovic,et al.  Clinical Prediction Models , 2013 .

[34]  Yvonne Vergouwe,et al.  A simple method to adjust clinical prediction models to local circumstances , 2009, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[35]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.